Colitis, Ulcerative Clinical Trial
Official title:
Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treatment
Confocal laser endomicroscopy (CLE) is a novel method in evaluation of microscopic
structures in vivo. The examination is carried out with a confocal laser endomicroscope,
which is either part of the endoscope (manufactured by Pentax) or probe based (manufactured
by Cellvizio). Hereby, all parts of the gastrointestinal (GI) tract can be examined. The
method has potential to replace conventional microscopy and the dynamic nature of the
procedure allows visualization of structures and cellular processes in almost real-time.
This provides us with a potentially new diagnostic tool with a promising future. To date
only a few studies have been published on inflammatory bowel disease (IBD) and in the
literature high-quality research is still lacking.
The project consists of a blinded prospective observation and methodology study including
inter- and intra-observation of patients with proctitis before and after initiation of local
treatment.
Hypothesis: CLE can be used to assess the degree and extend of acute and chronic
inflammation and treatment response in patients with ulcerative colitis and is a sensitive
supplementary to conventional diagnostics.
Confocal laser endomicroscopy findings in patients with proctosigmoiditis before and after
initiation of treatment
Background Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis.
Crohn's disease often strikes the terminal ileum, but may occur from the mouth to the anus.
It is characterized by segmental spreading with transmural inflammation and occasional
presence of granulomas in the tissue samples. Ulcerative colitis is only found in the colon
and involves in practice always the rectum. The inflammation is limited to the mucosa and
submucosa, and the diffusion is continuous.
The development of endoscopy has made these procedures a central part of the diagnostic and
therapeutic management of patients with gastrointestinal diseases, including IBD. The entire
gastrointestinal tract is now available for inspection and therapy. A limitation of these
studies is that the histology, which is often essential for the diagnosis and treatment of
the patient, cannot always be precisely evaluated by a conventional examination. The proper
handling of detected lesions require in addition to the endoscopic evaluation, a
histological evaluation of the tissue involved, making tissue samples necessary in order to
obtain a definitive diagnosis and thus optimal handling. Therefore, during the endoscopic
procedure tissue samples from the intestinal mucosa must be taken, which rarely involves a
greater risk to the patient, but causes a delay, due to preparation time for the
histological analysis and in some cases even due to re-examination if histopathology is
negative. In the treatment of IBD the endoscopic assessment of the severity and extension is
absolutely essential for the choice of treatment. The "Gold standard" for the optimal
treatment is called "deep" remission, defined by clinical and endoscopic remission as
assessed by conventional endoscopy.
Within recent years a new approach was introduced, wherein the microscopic structures of the
intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The
technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser
device, which is inserted or build into an endoscope, and used as an illuminator of the
lining of a small area and at a precise depth. The tissue is first added with fluorescence
by intravenous administration. The reflection of the mucosa is captured in a focused area
and magnified by which a two-dimensional image of mucosal microscopic structures is formed.
This provides us with an "optical biopsy", which can be compared with a similar microscopic
image.
This provides us with a potential opportunity for immediate diagnosing and targeted therapy
during the same procedure. The optical biopsy is stored digitally in such a way that it can
also be evaluated postprocedure. During CLE multiple frames are generated per second, which
is stored continuously, thereby forming a movie sequence, so that the microscopic assessment
of the tissue becomes dynamic i.e. the flow in the small vessels may be observed.
A current hypothesis about the pathogenesis of IBD is that a defective barrier function may
be a key element. The intestinal barrier is composed of epithelial cells, which are bound
together by the so-called "tight junctions". Experimental studies have shown an increased
intestinal permeability in IBD patients and that the degree of permeability is a prognostic
indicator for the relapse of Crohn's disease. In CLE-studies, the defective barrier function
has been identified in vivo as an efflux of fluorescein through the intestinal wall and
demonstrated to be significantly greater in IBD patients compared to a healthy control
group. The spacing between the epithelial cells are also increased. In patients in remission
a defective barrier function predisposes to relapse of their disease. However, it is not
possible to realize this dysfunction by a conventional histological examination, as well as
other parameters, which require a dynamic microscopic evaluation. By implementing CLE the
sensitivity of the endoscopic assessment may increase, which may change not only the
characteristics of "deep" remission, but also assessment of the diseases activity.
CLE is at present a rapidly growing field of development which has primarily been used in
connection with endoscopy of the digestive tract, but also has been used in connection with
endoscopy of the urinary and respiratory tract. CLE have been shown, to reduce the number of
tissue samples significantly without compromising the diagnosis. Furthermore, several
studies suggest that CLE can contribute to a more accurate diagnosis, and preliminary
studies suggest that the degree of the disease can be estimated better compared to
conventional endoscopy. Yet, there is no data evaluating the applicability of the method in
relation to monitoring of treatment response and as a real prognostic tool. CLE is a new
method, and therefore still many unresolved issues and areas to be clarified exist before
the technology can finally be implemented in the daily practice.
There is in the research group led by professor of endoscopy Peter Vilmann several years
fostered a greater experience in the introduction of new methods. This includes the
implementation of relevant studies and the collection and publication of scientific data at
an international level, so that the modality can find its proper place for the diagnosis and
treatment of patients.
Introduction: By conventional colonoscopy, the degree and spread of inflammation is often
underestimated or overlooked in patients with acute inflammation due to insufficient
sensitivity. In ulcerative colitis the course of the disease and in particular the risk of
treatment failure is related to the degree of acute inflammation, which in addition to
clinical and endoscopic observations is assessed by changes in crypt architecture, and
infiltration of acute inflammatory cells in the lamina propria. The dissemination of the
disease is also particularly important for the choice of treatment, which changes
successively from suppositories to enemas and to systemic corticosteroids depending on the
proximal boundary of the inflammation. Taking tissue samples may partially prevent
underestimation, but this is time consuming, expensive and rarely leads to a radically
change of treatment strategy, since endoscopy is the reference in this context. The
literature suggest two classifications of inflammation based on CLE, which we partly - and
for a start, will use to estimate disease activity before and after initiation of treatment
and in a control group. In addition, personal observations will be recorded and analyzed.
This assessment will subsequently be used for an intra-and inter-observer study and a
stratification of CLE-observations in relation to acute inflammation and degree in tissue
samples.
Hypothesis: CLE can be used to assess the degree and extend of acute and chronic
inflammation and treatment response in patients with ulcerative colitis and is a sensitive
supplementary to conventional diagnostics.
Design: A blinded prospective observation and methodology study in patients before and after
initiation of topical steroid treatment with subsequent calculation of intra-and
inter-observer variability.
Method: Enrolled patients will be examined by conventional colonoscopy and CLE before and
after initiation of topical treatment, respectively. The degree and distribution of acute
inflammation will be assessed by conventional microscopy (Mayo score), CLE (crypt
architecture, micro vascular changes and the presence of inflammatory cells in the lamina
propria and defective barrier function) and histology biopsies. It is expected that not
previously described CLE-finding will be found, and that these will be recorded and
evaluated as described above.
The terminal ileum and each colonic segment is (caecum, ascending colon, transversal colon,
descending colon, colon sigmoid and rectum) assessed as described above. CLE findings will
be graded for analysis according to the following scales:
Crypt Architecture: 1: Normal, 2: Changed shape, size and distribution, 3: Crypt destruction
and abscess
Micro vascular changes: 1: Normal, 2: Slightly higher in number and moderately dilated, 3:
Significantly higher in number and massively dilated
Infiltration of inflammatory cells: 1: No, 2: Presence <50% of the crypts, 3: Presence> 50%
of the crypts
Defective barrier function: 1: Normal, 2: Functional defect, 3: Structural defect
The correlation between histology (the "gold standard"), the Mayo score, which is a combined
clinical and endoscopic index, and CLE will be calculated. This applies to both IBD patients
as the control group. An intra-and inter-observer study is planned after the initial study,
where CLE operators are blinded with respect to each other. The pathologist is blinded to
conventional and CLE observations. CLE results are stratified in order to identify which of
the recorded CLE parameters correlates best with the other two methods, and is therefore
most suitable for further studies with focus on inflammation. In addition, a determination
of the relationship between CLE findings and the treatment effect for the individual patient
is conducted.
Statistical method: Comparison of CLE-findings in relation to the Mayo score and histology
is made using Spearman correlation analysis. To evaluate the treatment effect the Wilcoxon
Signed Rank test is used. In the inter-and intra-observer study weighted kappa statistics
are used.
Patient: A complete sample-size calculation has been made for the inter-and intra-observer
study of the individual CLE parameters by 3 observers. If possible, to achieve a kappa value
of 0.9 with a confidence interval of 0.05, there must be 122 observations. If we register
Mayo score, CLE parameters and take tissue samples for pathology in all the abovementioned
intestinal segments during two endoscopies, 14 observations for each patient will be
registered which subsequently are assessed in relation to each of the parameters used in the
study. If there is no waivers, all ileocolonoscopies are fulfilled and all CLE observations
can be analyzed, only 9 patients needs to be included. It is assumed, however, that if only
25% of the expected observations are obtained, since some CLE observations will be
unsatisfactory, some examinations will be interrupted, and some patients will only be only
evaluated once. Thus, 36 patients must be enrolled in the study to achieve the desired
strength, of which 10 are in the control group.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Completed |
NCT03494764 -
Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
|
Phase 2 | |
Recruiting |
NCT03937609 -
TITRATE (inducTIon for acuTe ulceRATivE Colitis)
|
Phase 4 | |
Completed |
NCT00503243 -
Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03606499 -
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
|
||
Completed |
NCT02537210 -
Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis
|
N/A | |
Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
Completed |
NCT00488631 -
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT00928681 -
A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis
|
Phase 1 | |
Recruiting |
NCT05242484 -
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT01036022 -
Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT03841045 -
Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
|
||
Active, not recruiting |
NCT05528510 -
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT02825914 -
CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)
|
N/A | |
Recruiting |
NCT06049017 -
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT04567628 -
Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
|
||
Withdrawn |
NCT05999708 -
A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT05611671 -
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
|
Phase 2 | |
Active, not recruiting |
NCT03596645 -
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03648541 -
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
|
Phase 2 |